Safety of immune checkpoint inhibitors for cancer treatment: real-world retrospective data analysis from Qatar (SAFE-ICI-Q study).

ABSTRACT:

Introduction

Immune checkpoint inhibitors (ICIs) have significantly improved the therapeutic landscape of multiple malignancies. It becomes critical to understand the incidence, profile, and consequences of immune-related adverse events (irAEs) within real-world populations.

Aim

We aimed to assess the safety profile of ICIs in adult cancer patients at the National Center for Cancer Care and Research (NCCCR), Qatar, and explore the factors associated with irAEs, including the impact of irAEs on the survival outcomes.

Methods

This retrospective study included adult cancer patients who received at least one dose of an ICI between January 1, 2015, and January 1, 2020. Data was collected from electronic health records and institutional adverse drug reaction (ADR) reporting

SUBMITTER: Omar NE 

PROVIDER: S-EPMC12605147 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature